Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
6.32
+0.13 (2.10%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 9.17, with a low estimate of 8.50 and a high estimate of 10. The average target predicts an increase of 45.09% from the current stock price of 6.32.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for CTKB stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $8.5 | Buy | Maintains | $8 → $8.5 | +34.49% | Nov 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8.5 → $8 | Buy | Maintains | $8.5 → $8 | +26.58% | Aug 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8.5 | Buy | Maintains | $10 → $8.5 | +34.49% | May 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +58.23% | Mar 6, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +58.23% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
208.80M
from 193.02M
Increased by 8.18%
Revenue Next Year
236.39M
from 208.80M
Increased by 13.21%
EPS This Year
-0.06
from -0.09
EPS Next Year
0.06
from -0.06
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 216.7M | 247.9M | 283.5M |
| Avg | 208.8M | 236.4M | 265.6M |
| Low | 199.0M | 213.2M | 232.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 12.3% | 18.7% | 19.9% |
| Avg | 8.2% | 13.2% | 12.4% |
| Low | 3.1% | 2.1% | -1.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.05 | 0.14 | 0.17 |
| Avg | -0.06 | 0.06 | 0.09 |
| Low | -0.08 | -0.02 | 0.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 184.0% |
| Avg | - | - | 46.6% |
| Low | - | - | -66.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.